All of this comes as a key federal agency is considering stricter oversight of the growing--and dangerously under-regulated--field of compounding pharmacies in the United States. Large-scale compounding pharmacies today are acting as quasi drug manufacturers, and the industry has grown in recent years. In 2012, this captured national attention when contaminated steroid injections prepared by a major compounding pharmacy in Massachusetts caused a multi-state outbreak of fungal meningitis. Meanwhile, 60 percent of states do not even require compounding pharmacies to report serious adverse drug events and reactions related to sterile compounding. One immediate and significant step forward would be compulsory reporting of adverse events as they happen for compounding pharmacies.

Source: Huffington Post September 12, 2016 16:41 UTC